The complexity of Daiichi Sankyo Inc.’s NDA for the anticoagulant Savaysa (edoxaban) appears to have resulted in mid- and late-cycle meetings that involved an extraordinary number of participants from FDA and the sponsor.
A total of 70 people were involved in a 90-minute, mid-cycle teleconference June 24, including 40 staffers from FDA and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?